Oral Surgery Robot Company Yangshan Medical Completes Pre-A Round Financing of Tens of Millions of RMB

*Image source: Yangshan Medical official WeChat account

DentalGoodNews | Shanghai Yangshan Medical Technology Co., Ltd. (hereinafter referred to as "Yangshan Medical"), an oral surgery robot company, recently completed a pre-A round financing of tens of millions of RMB, co-led by Shanlan Capital and Yuanyi Capital, with Bluerun Ventures, an early-stage technology investment institution, continuing to follow as an existing shareholder.

According to official disclosures, Yangshan Medical provides full-process solutions for oral and maxillofacial surgery using robots, artificial intelligence, and innovative passive medical devices as tools. Its independently developed first unobstructed surgical robot in China using new navigation technology will soon be applied to oral implant surgery. The product features core advantages including zero registration, no obstruction, anti-interference, fast surgery, short learning curve, and miniaturization, and is combined with an artificial intelligence technology platform to assist doctors in completing surgeries.

*Image source: Yangshan Medical official WeChat account

In addition, another product of Yangshan Medical, the Dental Implant Distractor (DID), is the world's first of its kind, revolutionizing the vascularized fibula graft technique in traditional mandibular defect reconstruction. This achievement won the National Science and Technology Progress Award (Second Class) in 2019 and entered the National Medical Products Administration's special review procedure for innovative medical devices in 2025.

Previously, the Stomatology Hospital of Air Force Medical University completed the world's first autonomous oral surgery robot-led orthognathic surgery, marking China's technological breakthrough in the field of oral surgery robots. Hang Yuankai, investment director of Shanlan Capital, stated that the medical surgical robot track is experiencing dual dividends of technological implementation and demand release. Tang Yinan, managing director of Yuanyi Capital, believes that robot technology is driving oral implantology into a new stage of precision and intelligence, and this transformation may generate a 100-billion-level track.